Management guidelines for stage III non-small cell lung cancer

Jazieh, Abdul Rahman; Zeitouni, Mohammed; Alghamdi, Majed; Alrujaib, Mashael; Lotfi, Shukri; Daff, Saleh Abu; Al-Omair, Ameen; Al-Shehri, Saleh; Alhusaini, Hamed; Allehebi, Ahmed; Ansari, Jawaher; Al-Nassar, Muath; Jafar, Hassan; Al-Farsi, Abdulaziz; Abdelhafeez, Nafisa; Alkattan, Khaled

doi:10.1016/j.critrevonc.2020.103144

Cited by 20 publications

(15 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LANSCLC is acknowledged as a highly heterogeneous stage of disease with diverse tumor burden and clinical factors, and several clinical features have emerged to affect the survival. [25][26][27] Based on previous reports and our experience, patient, tumor and treatment-related factors were brought into the univariate and multivariate analyses, and ultimately seven parameters of sex, smoking history, histology (including EGFR mutation status), overall TNM stage, chemotherapy sequence, PTV volume and RP grade were determined as important prognostic factors.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy

et al. 2021

View full text Add to dashboard Cite

Background: This study aimed to establish a predictive nomogram integrating epidermal growth factor receptor (EGFR) mutation status for 3-and 5-year overall survival (OS) in unresectable/inoperable stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiotherapy. Methods: A total of 533 stage III NSCLC patients receiving chemoradiotherapy from 2013 to 2017 in our institution were included and divided into training and testing sets (2:1). Significant factors impacting OS were identified in the training set and integrated into the nomogram based on Cox proportional hazards regression. The model was subject to bootstrap internal validation and external validation within the testing set and an independent cohort from a phase III trial. The accuracy and discriminative capacity of the model were examined by calibration plots, C-indexes and risk stratifications.Results: The final multivariate model incorporated sex, smoking history, histology (including EGFR mutation status), TNM stage, planning target volume, chemotherapy sequence and radiation pneumonitis grade. The bootstrapped C-indexes in the training set were 0.688, 0.710 for the 3-and 5-year OS. For external validation, C-indexes for 3-and 5-year OS were 0.717, 0.720 in the testing set and 0.744, 0.699 in the external testing cohort, respectively. The calibration plots presented satisfying accuracy. The derivative risk stratification strategy classified patients into distinct survival subgroups successfully and performed better than the traditional TNM staging. Conclusions: The nomogram incorporating EGFR mutation status could facilitate survival prediction and risk stratification for individual stage III NSCLC, providing information for enhanced immunotherapy decision and future trial design.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Approximately 20% to 30% of NSCLC patients are classified as stage III, and treatment for stage III NSCLC is complex and controversial ( 9 , 10 ). Neoadjuvant chemotherapy before surgery and adjuvant chemotherapy or definitive concurrent chemoradiotherapy after the operation were the standard therapies for resectable IIIA and partial stage IIIB patients ( 8 , 11 ).…”

Section: Discussionmentioning

confidence: 99%

Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review

Jia

Zhou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

The prognosis of patients with stage IIIC non-small-cell lung cancer (NSCLC) is poor due to the loss of surgical treatment opportunities. Improving the prognosis of these patients with IIIC NSCLC urgently needs to be addressed. Here, we report a stage IIIC (T4N3M0 IIIC (AJCC 8th)) NSCLC patient treated with 2 cycles of anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis therapy; after two cycles of treatment, the patient achieved a partial response and obtained the opportunity for surgical treatment. After the operation, the patient achieved a pathological complete response and successfully transformed from unresectable stage IIIC lung cancer to radical surgery (ypT0N0M0). Our study is expected to provide new ideas for treating patients with unresectable stage IIIC NSCLC in the future.

show abstract

“…Lung cancer is one of the most commonly diagnosed cancers and remains the main cause of cancer-related death worldwide. 1 Among the common types of lung cancer, $85% of clinical cases are non-small cell lung cancer (NSCLC), 2,3 which has low overall cure and survival rates. 4,5 Radiotherapy plays a prominent role in the treatment of NSCLC, 6 but the intrinsic or acquired radioresistance greatly impairs the efficacy of radiotherapy, 7 resulting in its failure.…”

Section: Introductionmentioning

confidence: 99%

Increased activation of cGAS‐STING pathway enhances radiosensitivity of non‐small cell lung cancer cells

et al. 2022

View full text Add to dashboard Cite

Background Radiotherapy is an effective therapeutic approach widely used clinically in non‐small cell lung cancer (NSCLC), but radioresistance remains a major challenge. New and effective radiosensitizing approaches are thus urgently needed. The activation of DNA‐sensing cyclic GMP‐AMP synthase (cGAS)‐stimulator of interferon genes (STING) pathway has become an attractive therapeutic target, but the relationship between activation of cGAS‐STING pathway and radiosensitization of NSCLC cells remains unknown. Methods Considering low expression of cGAS‐STING pathway genes in NSCLC, including STING, we used an activator (STING agonist, dimeric amidobenzimidazole [diABZI]) of cGAS‐STING pathway and increased activation factor (DNA double strand breaks) of cGAS‐STING pathway to respectively reinforce the activation of cGAS‐STING pathway in NSCLC cells. We then investigated the effect of increased activation of cGAS‐STING pathway on the proliferation of H460 and A549 cells by CCK‐8 and colony formation assays, and revealed the underlying mechanism. Results We found that both diABZI and the increased DNA double strand breaks could sensitize NSCLC cells to irradiation. Mechanically, our results showed that the increased activation of cGAS‐STING pathway enhanced radiosensitivity by promoting apoptosis in NSCLC cells. Conclusion Taken together, we concluded that diABZI could be used as a radiosensitizer in NSCLC cells, and targeting the activation of cGAS‐STING pathway has a potential to be a new approach for NSCLC radiosensitizing.

show abstract

Management guidelines for stage III non-small cell lung cancer

Cited by 20 publications

References 60 publications

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy

Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review

Increased activation of cGAS‐STING pathway enhances radiosensitivity of non‐small cell lung cancer cells

Contact Info

Product

Resources

About